SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Celgene International Inc (Last) (First) (Middle) 86 MORRIS AVENUE C/O CELGENE CORP (Street) SUMMIT NJ 07901 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/01/2014	3. Issuer Name and Ticker or Trading Symbol GLOBEIMMUNE INC [ GBIM ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	2,160,682(1)	(1)	D(2)
Series D Convertible Preferred Stock	(1)	(1)	Common Stock	8,650,519(1)	(1)	D(2)
Series E Convertible Preferred Stock	(1)	(1)	Common Stock	1,765,888(1)	(1)	D(2)
Warrants to Purchase Series C Preferred Stock (right to buy)	(3)	(3)	Common Stock	2,096,328(1)	$1.445(1)	D(2)

1. Name and Address of Reporting Person* Celgene International Inc (Last) (First) (Middle) 86 MORRIS AVENUE C/O CELGENE CORP (Street) SUMMIT NJ 07901 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* CELGENE CORP /DE/ (Last) (First) (Middle) 86 MORRIS AVENUE (Street) SUMMIT NJ 07901 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. Each share of Series C Convertible Preferred Stock, Series D Convertible Preferred Stock and Series E Convertible Preferred Stock (collectively, "Preferred Stock") will automatically convert on a 1-for-31.39 basis into shares of common stock of the Issuer (i.e., 1 share of common stock for every 31.39 shares of any series of Preferred Stock) upon the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in column 3 and the warrant exercise price reported in column 4 do not reflect such conversion. Each share of Preferred Stock is convertible into shares of common stock at any time at the holder's election and there is no expiration date for any series of Preferred Stock.

2. These shares and warrants are owned directly by Celgene International Inc., a wholly owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold, convert, exercise and dispose of all shares and warrants. Celgene disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.

3. The warrants to purchase the number of shares of common stock reported in column 3 are exercisable at any time at the holder's election. The warrants are exerciable until their expiration on the later of May 14, 2019 or five years after the closing of the Issuer's initial public offering.

Remarks:

	/s/ Jonathan Biller, Treasurer of Celgene International Inc. /s/ Perry Karsen, Executive Vice President and Chief Operations Officer of Celgene Corporation	07/01/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.